Skip to content

VYNE THERAPEUTICS INC.

VYNE

CIK 0001566044

← back to feed
Revenue (TTM)
$478K
+13.8% YoY Q1 May 2026
Net Income (TTM)
−$30.11M
+33.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.70
+33.3% YoY Q1 May 2026
Gross Margin
-5,105.6%
Q1 May 2026
Operating Margin
-7,038.9%
Q1 May 2026
Net Margin
-6,298.7%
Q1 May 2026
Free Cash Flow (TTM)
−$29M
Q1 May 2026
Cash
$24.63M
Q1 May 2026
Total Debt
$0
Q1 May 2026
Shares Outstanding
33.35M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings